1. Solid Tumors & Glioblastoma Breakthroughs
- Advanced Gastric / Gastroesophageal (GEJ) Cancer (China)
In what’s being hailed as the world’s first randomized controlled trial (RCT) of CAR‑T therapy for solid tumors, patients with advanced gastric or GEJ cancer treated with satri‑cel (CLDN18.2-directed CAR‑T) exhibited a 40% improvement in overall survival—7.9 months vs. 5.5 months—and significantly longer progression-free survival (3.3 vs. 1.8 months) compared to standard care. https://www.theguardian.com/science/2025/may/31/immunotherapy-trial-helps-cancer-patients-with-tumours-live-40-longer?
Meanwhile, another study reported tumor shrinkage in 62% of recurrent glioblastoma patients treated with a dual-target CAR‑T (targeting EGFR and IL‑13Rα2), administered via cerebrospinal fluid, with manageable neurotoxicity and some patients achieving over one-year disease stability. https://www.reuters.com/business/healthcare-pharmaceuticals/gileads-car-t-cell-therapy-shows-promise-deadly-brain-cancer-2025-06-01/? - Gastrointestinal (GI) Cancers – CLDN18.2-related Trials
The phase 1 CT041-CG4006 trial evaluating satri‑cel in CLDN18.2-positive GI cancers showed a robust overall response rate (ORR) of 38.8%, disease control in 91.8%, median PFS of 4.4 months, and median overall survival (OS) of 8.8 months. The pivotal phase 1/2 CT041‑ST‑01 trial is underway, having met its primary endpoint with significant PFS improvement versus physician’s choice in patients who failed multiple prior treatments. https://www.onclive.com/view/targeted-car-t-cell-therapies-show-early-efficacy-in-solid-tumors-with-focus-on-mitigating-toxicity? - Diffuse Midline Glioma (Brain Tumors)
In a phase 1 trial targeting GD2 in H3K27M-mutated gliomas, major tumor reductions were observed in 4 of 11 patients, with 1 patient achieving a complete response that has lasted over 30 months. Intracerebroventricular (ICV) administration arms are also being explored, including approaches without lymphodepletion. https://www.onclive.com/view/targeted-car-t-cell-therapies-show-early-efficacy-in-solid-tumors-with-focus-on-mitigating-toxicity? - Malignant Pleural Mesothelioma
A Phase 1/2 study combining mesothelin-directed CAR‑T therapy with pembrolizumab yielded a striking 1-year OS rate of 83%. Two patients achieved complete metabolic responses, and eight maintained stable disease for at least 6 months. https://www.onclive.com/view/targeted-car-t-cell-therapies-show-early-efficacy-in-solid-tumors-with-focus-on-mitigating-toxicity?
2. Hematologic Malignancies: New Targets & Long-Term Data
- Relapsed/Refractory DLBCL (Rapcabtagene autoleucel / YTB323)
This next-gen, CD19-directed CAR‑T distinguishes itself with preserved T-cell stemness and ultra-fast manufacturing (<2 days). https://www.sciencedirect.com/science/article/abs/pii/S2152265025023377 - Chronic Lymphocytic Leukemia (CLL) & Richter Transformation (GLPG5201)
The EUPLAGIA-1 phase I/II trial of GLPG5201 (CD19 CAR‑T) demonstrated an ORR of 86.7% and CR rate of 66.7%, with only grade ≤ 2 CRS reported and no neurotoxicity. https://www.frontiersin.org/journals/hematology/articles/10.3389/frhem.2025.1610794/full? - Multiple Myeloma (MM): Next‑Generation CAR‑Ts
- BMS-986393 (GPRC5D-targeted): In a phase 1 trial, ORR was 96%, CR rate 46%, with durable responses and manageable CRS/ICANS.
- CT071 (GPRC5D-targeted): Produced via rapid CARcelerate platform (~30-hour manufacturing). Among 17 patients, ORR was 94.1%, CR rate 52.9%, with MRD negativity in most.
- Cilta‑cel in Smoldering MM (CAR‑PRISM trial): Against high‑risk smoldering MM, this phase II trial showed 100% ORR and 50% CR at 28 days, with no progression at 6-month median follow-up.
https://www.frontiersin.org/journals/hematology/articles/10.3389/frhem.2025.1610794/full?
3. Autoimmune Diseases & Beyond: Off‑the‑Shelf & Regulatory CAR‑T
- CRISPR Therapeutics – CTX112
An allogeneic (off-the‑shelf) CAR‑T in Phase I for systemic lupus erythematosus (SLE), with basket trial expansion to include systemic sclerosis and inflammatory myositis. Mid‑2025 updates are expected. https://www.biospace.com/drug-development/5-car-t-cell-therapies-with-autoimmune-readouts-in-2025? - Autolus – obe‑cel (Obecabtagene autoleucel)
Approved for B‑ALL, obe‑cel is now being trialed in autoimmune SLE (CARLYSLE Phase I), with data anticipated in Q1 2025. https://www.biospace.com/drug-development/5-car-t-cell-therapies-with-autoimmune-readouts-in-2025?
The CAR‑T therapy front has dramatically broadened in 2025, no longer confined to blood cancers but moving into solid tumors, autoimmune disorders, and innovative delivery systems. Highlights include:
- First successful RCT in solid tumors (gastric/GEJ cancer achieving significant survival gains).
- Impressive glioblastoma shrinkage and GI cancer responses in early trials.
- Next-gen hematologic CAR‑Ts with streamlined manufacturing and improved safety/effectiveness.
- Autoimmune and transplant applications showing the field’s expansion into immune modulation beyond oncology.